SPOTLIGHT -
Dr. Koo on Novel Technological and Therapeutic Advancements in Prostate Cancer
Phillip J. Koo, MD, discusses ongoing areas of technological and therapeutic advancements within the prostate cancer landscape.
Read More
PSMA-Targeted 18F-DCFPyL PET/CT in High-Risk Prostate Cancer
An interpretation of the OSPREY study of 18F-DCFPyL injection in patients with high-risk prostate cancer and implications of its use.
Phenotypic Biomarkers in Advanced Prostate Cancer
A discussion regarding the use of PSMA PET imaging to detect phenotypic biomarkers that may simplify approaches to precision medicine in advanced prostate cancer.
Dr. Koo on the Need for Next-Generation Imaging in Prostate Cancer
Phillip J. Koo, MD, discusses the need for next-generation imaging in prostate cancer.
Dr. Koo on the Actionability of Next-Generation Imaging Results in Prostate Cancer
Phillip J. Koo, MD, division chief of Diagnostic Imaging, Banner MD Anderson Cancer Center, discusses the actionability of next-generation imaging results in prostate cancer.
Dr. Koo on Metastasis-Directed Therapy in Prostate Cancer
Phillip J. Koo, MD, division chief of Diagnostic Imaging, Banner MD Anderson Cancer Center, discusses the use of metastasis-directed therapy in prostate cancer.
Dr. Koo on New Management Strategies for Prostate Cancer
Phillip J. Koo, MD, discusses new management strategies for patients with prostate cancer.
Dr. Koo on Next-Generation Imaging in Prostate Cancer
Phillip J. Koo, MD, discusses next-generation imaging tools in prostate cancer.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making